TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14986414

Group type: EXPERIMENTAL
Intervention: Assistive torque system controlled by EMG signals
Number of subjects: 5

Group type: COMPARATOR
Intervention: Able-bodied individuals
Number of subjects: 5
Study: 10966532

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 8980590

Group type: EXPERIMENTAL
Intervention: Ivermectin (up to 4 annual doses)
Number of subjects: 948

Group type: EXPERIMENTAL
Intervention: Ivermectin (up to 10 doses at 6-month intervals)
Number of subjects: 948

Group type: EXPERIMENTAL
Intervention: Ivermectin (both regimens)
Number of subjects: 948
Study: 7936988

Group type: EXPERIMENTAL
Intervention: New two-axial conformation technique
Number of subjects: 0

Group type: COMPARATOR
Intervention: Old conformation technique
Number of subjects: 0

Group type: COMPARATOR
Intervention: Two-opposed technique
Number of subjects: 0

Group type: COMPARATOR
Intervention: Box technique
Number of subjects: 0
Study: 2905711

Group type: EXPERIMENTAL
Intervention: Cetamolol 15 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 29398050

Group type: EXPERIMENTAL
Intervention: Insulin therapy
Number of subjects: 285

Group type: COMPARATOR
Intervention: Statin use
Number of subjects: 285
Study: 28497511

Group type: EXPERIMENTAL
Intervention: Trainees who successfully lost/maintained weight
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Trainees who lost/regained weight
Number of subjects: 219

Group type: COMPARATOR
Intervention: Patients who did not lose weight
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Female trainees who successfully lost weight
Number of subjects: 219
Study: 26139745

Group type: EXPERIMENTAL
Intervention: GA plus epidural (study group)
Number of subjects: 86

Group type: COMPARATOR
Intervention: GA only (control group)
Number of subjects: 86
Study: 23221315

Group type: EXPERIMENTAL
Intervention: Baseline factors predictive of drinking patterns
Number of subjects: 143
Study: 21205115

Group type: EXPERIMENTAL
Intervention: Insulin glulisine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Insulin aspart
Number of subjects: 30
Study: 18458219

Group type: EXPERIMENTAL
Intervention: Candesartan (8-16 mg once daily)
Number of subjects: 257

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 257
Study: 16451284

Group type: EXPERIMENTAL
Intervention: Short-burst oxygen therapy
Number of subjects: 40
Study: 12664205

Group type: EXPERIMENTAL
Intervention: Arthroscopic stabilization followed by rehabilitation
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard therapy of immobilization and rehabilitation
Number of subjects: 24
Study: 11247199

Group type: EXPERIMENTAL
Intervention: Herbal oil massage
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Sesame oil massage
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Mustard oil massage
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Mineral oil massage
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control (no massage)
Number of subjects: 125
Study: 7558363

Group type: EXPERIMENTAL
Intervention: Cervitec varnish (1% chlorhexidine and thymol) applied at baseline, after 3-4 months, and after 8-9 months.
Number of subjects: 502

Group type: COMPARATOR
Intervention: Control tooth (untreated).
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Cervitec varnish application.
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Salivary mutans streptococci estimation.
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Plaque mutans streptococci estimation.
Number of subjects: 502
Study: 2084744

Group type: EXPERIMENTAL
Intervention: Facial screening
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 366484

Group type: EXPERIMENTAL
Intervention: Cefazolin
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Penicillin
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 31796225

Group type: EXPERIMENTAL
Intervention: LAIV4 2017-2018 (A/Slovenia)
Number of subjects: 200

Group type: COMPARATOR
Intervention: LAIV4 2015-2016 (A/Bolivia)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Trivalent LAIV (LAIV3) 2015-2016 (A/Bolivia)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: A/Slovenia vaccine strain
Number of subjects: 200

Group type: COMPARATOR
Intervention: A/Bolivia strain
Number of subjects: 200
Study: 31640757

Group type: EXPERIMENTAL
Intervention: ERAS pathway
Number of subjects: 640

Group type: COMPARATOR
Intervention: Conventional care (non-ERAS group)
Number of subjects: 640
Study: 28628269

Group type: EXPERIMENTAL
Intervention: Methylphenidate extended-release oral suspension (MEROS) 60 mg under fed conditions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methylphenidate extended-release oral suspension (MEROS) 60 mg under fasting conditions
Number of subjects: 0
Study: 25894061

Group type: EXPERIMENTAL
Intervention: ICECAP-A (non-weighted scores)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ICECAP-A (value-weighted scores)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ICECAP-A
Number of subjects: 0

Group type: COMPARATOR
Intervention: EQ-5D-3L
Number of subjects: 0
Study: 23832498

Group type: EXPERIMENTAL
Intervention: Gefitinib
Number of subjects: 203

Group type: COMPARATOR
Intervention: Gemcitabine plus cisplatin (GP)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: EGFR-TKI (second-line treatment)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Both groups (gefitinib and GP)
Number of subjects: 203
Study: 21464401

Group type: EXPERIMENTAL
Intervention: PTK787/ZK 222584 (PTK/ZK) with FOLFOX4
Number of subjects: 855

Group type: COMPARATOR
Intervention: Placebo with FOLFOX4
Number of subjects: 855

Group type: EXPERIMENTAL
Intervention: PTK787/ZK 222584 (PTK/ZK) with FOLFOX4 in patients with high LDH
Number of subjects: 855
Study: 19801201

Group type: EXPERIMENTAL
Intervention: SRS plus WBRT
Number of subjects: 58

Group type: COMPARATOR
Intervention: SRS alone
Number of subjects: 58
Study: 16760316

Group type: EXPERIMENTAL
Intervention: MCV (Meningococcal group C polysaccharide-protein conjugate vaccine)
Number of subjects: 95
Study: 15052244

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 30

Group type: COMPARATOR
Intervention: Metoprolol (Control)
Number of subjects: 30
Study: 11442734

Group type: EXPERIMENTAL
Intervention: Convex toothbrush
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Multilevel toothbrush
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Flat trimmed toothbrush
Number of subjects: 25
Study: 9014018

Group type: EXPERIMENTAL
Intervention: Physical signs (liver enlargement, parotid swelling, retches and tremor in the morning, hoarseness)
Number of subjects: 492

Group type: EXPERIMENTAL
Intervention: Biological markers (serum GGT, ASAT, MCV, urate levels)
Number of subjects: 492
Study: 7715916

Group type: EXPERIMENTAL
Intervention: lovastatin
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: simvastatin
Number of subjects: 150

Group type: COMPARATOR
Intervention: fenofibrate
Number of subjects: 150
Study: 2927328

Group type: EXPERIMENTAL
Intervention: 'Know Your Midwife' scheme
Number of subjects: 503

Group type: COMPARATOR
Intervention: Standard hospital care
Number of subjects: 503
Study: 31004770

Group type: EXPERIMENTAL
Intervention: Advance care planning intervention
Number of subjects: 460

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 460
Study: 28878452

Group type: EXPERIMENTAL
Intervention: Spinal support device (SSD)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (bed rest in supine position)
Number of subjects: 20
Study: 26475714

Group type: EXPERIMENTAL
Intervention: Atraumatic Restorative Treatment (ART) in children undergoing oncohematological treatment (E)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Atraumatic Restorative Treatment (ART) in children not undergoing oncohematological treatment (C)
Number of subjects: 38
Study: 24432673

Group type: EXPERIMENTAL
Intervention: Fangfeng Tongsheng Granule (FTG) at a daily dose of 3 g, twice per day for 3 days.
Number of subjects: 324

Group type: COMPARATOR
Intervention: Simulated agent granules at the same dose and dosage as FTG.
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Fangfeng Tongsheng Granule (FTG)
Number of subjects: 324

Group type: COMPARATOR
Intervention: Simulated agent granules
Number of subjects: 324
Study: 22019575

Group type: EXPERIMENTAL
Intervention: Basic diagnostic headache diary (BDHD) used before the first visit to the headache centre for at least 1 month
Number of subjects: 626

Group type: COMPARATOR
Intervention: Clinical interview alone without BDHD
Number of subjects: 626
Study: 19771459

Group type: EXPERIMENTAL
Intervention: MSCT
Number of subjects: 24
Study: 16477923

Group type: EXPERIMENTAL
Intervention: Dexamethasone 96 mg daily
Number of subjects: 38

Group type: COMPARATOR
Intervention: Dexamethasone 16 mg daily
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 38
Study: 14727749

Group type: EXPERIMENTAL
Intervention: Normal brain perfusion SPECT data generated using Monte Carlo simulations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ictal brain perfusion SPECT data generated using Monte Carlo simulations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simulated data for inter-hemispheric asymmetry coefficients
Number of subjects: 0
Study: 10601410

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulins (IVIg) 0.4 g/kg body weight on 5 consecutive days
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 9108848

Group type: EXPERIMENTAL
Intervention: Diphtheria-tetanus-pertussis toxoids vaccine
Number of subjects: 3450

Group type: COMPARATOR
Intervention: Diphtheria-tetanus toxoids vaccine
Number of subjects: 3450
Study: 7503952

Group type: EXPERIMENTAL
Intervention: Normal saline infusion
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Dextran infusion
Number of subjects: 15
Study: 3901391

Group type: EXPERIMENTAL
Intervention: Ticlopidine
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 29806788

Group type: EXPERIMENTAL
Intervention: Diabetes self-management education (DSME) + peer leader diabetes self-management support (PL DSMS) (n = 119)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Enhanced usual care (EUC) (DSME + traditional DSMS with no PL; n = 102)
Number of subjects: 221
Study: 27253395

Group type: EXPERIMENTAL
Intervention: vLAB (virtual laboratory simulation)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Demonstration (live demonstration from a lab tutor)
Number of subjects: 189
Study: 24691504

Group type: EXPERIMENTAL
Intervention: ClearVoice-low
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: ClearVoice-medium
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: ClearVoice-high
Number of subjects: 46

Group type: COMPARATOR
Intervention: HiRes Fidelity 120
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: ClearVoice
Number of subjects: 46
Study: 21378086

Group type: EXPERIMENTAL
Intervention: Subacromial corticosteroid injection
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with home exercises
Number of subjects: 117
Study: 19440186

Group type: EXPERIMENTAL
Intervention: Coadministration of Delta9-THC and MDMA
Number of subjects: 16

Group type: COMPARATOR
Intervention: MDMA alone
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Coadministration of MDMA and THC
Number of subjects: 16

Group type: COMPARATOR
Intervention: THC alone
Number of subjects: 16

Group type: COMPARATOR
Intervention: MDMA
Number of subjects: 16
Study: 17727577

Group type: EXPERIMENTAL
Intervention: Desmopressin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 14714107

Group type: EXPERIMENTAL
Intervention: Linezolid 600 mg every 12 h for 7-21 days
Number of subjects: 544

Group type: COMPARATOR
Intervention: Vancomycin 1 g every 12 h for 7-21 days
Number of subjects: 544
Study: 11915093

Group type: EXPERIMENTAL
Intervention: Telemedicine (monitor time)
Number of subjects: 28

Group type: COMPARATOR
Intervention: On-site (real time)
Number of subjects: 28
Study: 9141123

Group type: EXPERIMENTAL
Intervention: Energy storing feet (ESF) - Otto Bock Dynamic Pro and Hanger Quantum
Number of subjects: 10

Group type: COMPARATOR
Intervention: Conventional feet (CF) - Otto Bock Multi Axial and Otto Bock Lager
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Overall preference
Number of subjects: 10
Study: 8243022

Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg/day for 3 weeks, followed by 10 mg/day for 9 weeks
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study: 3308241

Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 156

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study: 350144

Group type: EXPERIMENTAL
Intervention: Tetracycline hydrochloride capsules with various dispersity levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tetracycline hydrochloride capsules with magnesium carbonate and calcium salts
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tetracycline hydrochloride capsules
Number of subjects: 0
Study: 31564125

Group type: EXPERIMENTAL
Intervention: Immediate blended collaborative care intervention
Number of subjects: 40

Group type: COMPARATOR
Intervention: Waiting control group
Number of subjects: 40

Group type: COMPARATOR
Intervention: Waiting control group after six-month waiting period
Number of subjects: 40
Study: 31113408

Group type: EXPERIMENTAL
Intervention: Health coaching
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 28290057

Group type: EXPERIMENTAL
Intervention: Bovine colostrum supplementation (Col), 20 g/day for 14 days
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (Plac)
Number of subjects: 18
Study: 26196753

Group type: EXPERIMENTAL
Intervention: Biodegradable polymer biolimus-eluting stent (BES)
Number of subjects: 2707

Group type: COMPARATOR
Intervention: Durable polymer everolimus-eluting stent (EES)
Number of subjects: 2707
Study: 23651846

Group type: EXPERIMENTAL
Intervention: Nutrient infusion into mid-jejunum
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nutrient infusion into duodenum
Number of subjects: 20
Study: 21865355

Group type: EXPERIMENTAL
Intervention: Oral prednisone (AMIO-ON group)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Oral prednisone (AMIO-OFF group)
Number of subjects: 83
Study: 20161528

Group type: EXPERIMENTAL
Intervention: Ask-Advise-Refer (AAR) protocol
Number of subjects: 10
Study: 17160982

Group type: EXPERIMENTAL
Intervention: Factor analysis for boys
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Factor analysis for girls
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Central body fat distribution and centralized subcutaneous fat (factors 1 and 2)
Number of subjects: 400
Study: 15067098

Group type: EXPERIMENTAL
Intervention: Oral antibiotics (ciprofloxacin 200 mg and amoxicillin-clavulanate 375 mg every 8 h)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Intravenous antibiotics (ceftazidime 1 g every 12 h)
Number of subjects: 36
Study: 11444419

Group type: EXPERIMENTAL
Intervention: Beta-carotene (15 mg)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Lutein (15 mg)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Lycopene (15 mg)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 175
Study: 11367649

Group type: EXPERIMENTAL
Intervention: Tongmai Jiangzhi Oral Liquid (TJOL)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Capsulae Oenoth Erae Biennisolei (COEB)
Number of subjects: 41
Study: 7868490

Group type: EXPERIMENTAL
Intervention: Rifampicin
Number of subjects: 10
Study: 3248127

Group type: EXPERIMENTAL
Intervention: Dialysate with medium calcium concentration (1.34 +/- 0.03 mmol/L)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Dialysate with low calcium concentration (1.02 +/- 0.02 mmol/L)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Dialysate with high calcium concentration (1.68 +/- 0.07 mmol/L)
Number of subjects: 7
Study: 31995838

Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg
Number of subjects: 1239

Group type: EXPERIMENTAL
Intervention: Baricitinib 2 mg
Number of subjects: 1239

Group type: EXPERIMENTAL
Intervention: Baricitinib 1 mg
Number of subjects: 1239

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1239
Study: 29438463

Group type: EXPERIMENTAL
Intervention: DHP107 (200 mg/m2 orally twice daily days 1, 8, 15 every 4 weeks)
Number of subjects: 236

Group type: COMPARATOR
Intervention: i.v. paclitaxel (175 mg/m2 day 1 every 3 weeks)
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: DHP107
Number of subjects: 236

Group type: COMPARATOR
Intervention: i.v. paclitaxel
Number of subjects: 236
Study: 28051926

Group type: EXPERIMENTAL
Intervention: Complicated Grief Group Therapy (CGGT)
Number of subjects: 0
Study: 24674297

Group type: EXPERIMENTAL
Intervention: Standard care with 40 HBOT sessions
Number of subjects: 275

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 275
Study: 22575624

Group type: EXPERIMENTAL
Intervention: Sirolimus‐eluting stent (SES)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Paclitaxel‐eluting stent (PES)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Both SES and PES
Number of subjects: 112
Study: 21987195

Group type: EXPERIMENTAL
Intervention: Slow TUG test performance (>10.2 seconds) with normal hip BMD
Number of subjects: 1126

Group type: EXPERIMENTAL
Intervention: Slow TUG test performance with low hip BMD
Number of subjects: 1126

Group type: EXPERIMENTAL
Intervention: Normal TUG test performance with low hip BMD
Number of subjects: 1126

Group type: EXPERIMENTAL
Intervention: Both slow TUG test performance and low hip BMD
Number of subjects: 1126

Group type: COMPARATOR
Intervention: Normal TUG test performance and normal BMD
Number of subjects: 1126
Study: 18057985

Group type: EXPERIMENTAL
Intervention: MRI assessment of uterine volumes
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: MRI assessment of dominant fibroid volumes
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: MRI assessment of number of fibroids
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: MRI assessment of T(1) and T(2) weighted signal intensity of dominant fibroid
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Intraobserver agreement for observer A
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Intraobserver agreement for observer B
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Interobserver agreement for presence of adenomyosis
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Intraobserver agreement for observer A regarding adenomyosis
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Intraobserver agreement for observer B regarding adenomyosis
Number of subjects: 40
Study: 17712019

Group type: EXPERIMENTAL
Intervention: Meta-analyses including observational studies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Meta-analyses based on randomized controlled trials
Number of subjects: 0
Study: 15138363

Group type: EXPERIMENTAL
Intervention: Cisplatin and 5-fluorouracil (PF)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Mitomycin C, vincristine, cisplatin and 5-fluorouracil (MVPF)
Number of subjects: 94
Study: 11718446

Group type: EXPERIMENTAL
Intervention: Targeted intervention including feedback on practice and a seminar led by specialists
Number of subjects: 112

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 112
Study: 9144352

Group type: EXPERIMENTAL
Intervention: Synovial fluid from OA patients
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Synovial fluid from RA patients
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Synovial fluid activity
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Immunohistochemical analysis of RA synovium
Number of subjects: 49
Study: 7964484

Group type: EXPERIMENTAL
Intervention: T cell lines from treatment-responsive Lyme arthritis
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: T cell lines from treatment-resistant Lyme arthritis
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control group (treatment-responsive)
Number of subjects: 9
Study: 2826549

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Combination of Lisinopril and HCTZ
Number of subjects: 24
Study: 29308709

Group type: EXPERIMENTAL
Intervention: High-Intensity Functional Training (HIFT) <5-minute session
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High-Intensity Functional Training (HIFT) 15-minute session
Number of subjects: 10
Study: 26659583

Group type: EXPERIMENTAL
Intervention: HU + imatinib (HU 500 mg BID + imatinib 400 mg QD)
Number of subjects: 15

Group type: COMPARATOR
Intervention: HU alone (HU 500 mg BID)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: HU + imatinib
Number of subjects: 15

Group type: COMPARATOR
Intervention: HU alone
Number of subjects: 15
Study: 25913166

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 100

Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 100
Study: 23398960

Group type: EXPERIMENTAL
Intervention: Low-dose oral interferon alpha
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 20626664

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/d
Number of subjects: 440

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 440
Study: 18069726

Group type: EXPERIMENTAL
Intervention: Misspecified random-effects distribution in GLMMs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sensitivity analysis considering several random-effects distributions
Number of subjects: 0
Study: 16848808

Group type: EXPERIMENTAL
Intervention: Topical nitroglycerin ointment 0.2% b.i.d. for 2 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Botulinum toxin A injection (30 IU Botox)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Combination therapy of botulinum toxin and nitroglycerin
Number of subjects: 50

Group type: COMPARATOR
Intervention: Topical nitroglycerin ointment
Number of subjects: 50
Study: 12648882

Group type: EXPERIMENTAL
Intervention: Levormeloxifene
Number of subjects: 234

Group type: COMPARATOR
Intervention: Withdrawal of levormeloxifene treatment
Number of subjects: 234
Study: 10951830

Group type: EXPERIMENTAL
Intervention: Verapamil COER-24 180/240 mg (single daily dose at bedtime)
Number of subjects: 81